(Q51756383)

11 April 2018

title

Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. (English)

1 reference

11 April 2018

1 reference

1 reference

botulinum toxin type A

1 reference

Sheena K Aurora

1

1 reference

11 April 2018

Marek Gawel

2

1 reference

11 April 2018

Jan L Brandes

3

1 reference

11 April 2018

Suriani Pokta

4

1 reference

11 April 2018

Amanda M Vandenburgh

5

1 reference

11 April 2018

BOTOX North American Episodic Migraine Study Group

6

1 reference

11 April 2018

publication date

1 April 2007

1 reference

11 April 2018

published in

Headache

1 reference

11 April 2018

volume

47

1 reference

11 April 2018

issue

4

1 reference

11 April 2018

page(s)

486-499

1 reference

11 April 2018

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

The burden of migraine in Spain: beyond direct costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

The economic burden of migraine to society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Burden of migraine in the United States: disability and economic costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Workplace productivity. A review of the impact of migraine and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Is migraine a progressive brain disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Migraine: epidemiology, impact, and risk factors for progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Chronic daily headache: nosology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Migraine preventive medication reduces resource utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Migraine: preventive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Migraine--current understanding and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Topiramate for migraine prevention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Evidence for antinociceptive activity of botulinum toxin type A in pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Procedures for administering botulinum toxin type A for migraine and tension-type headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Efficacy of gabapentin in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Placebo effects mediated by endogenous opioid activity on mu-opioid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Belief or Need? Accounting for individual variations in the neurochemistry of the placebo effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Neurobiological mechanisms of the placebo effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Placebo response in clinical randomized trials of analgesics in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00624.X

10.1111/J.1526-4610.2006.00624.X

21 January 2018

Identifiers

DOI

1 reference

11 April 2018

1 reference

11 April 2018